REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Overview
NASDAQ:RVPH - US76152G1004 - Common Stock
RVPH Key Statistics, Chart & Performance
The current stock price of RVPH is 0.4916 USD. In the past month the price increased by 9.56%. In the past year, price decreased by -54.04%.
RVPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.79 | 699.97B | ||
| JNJ | JOHNSON & JOHNSON | 17.7 | 426.29B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.41 | 249.79B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.01 | 247.88B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.34 | 245.76B | ||
| MRK | MERCK & CO. INC. | 10.92 | 210.06B | ||
| PFE | PFIZER INC | 7.36 | 141.87B | ||
| SNY | SANOFI-ADR | 11.37 | 122.53B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.06 | 96.67B | ||
| GSK | GSK PLC-SPON ADR | 8.84 | 80.58B | ||
| ZTS | ZOETIS INC | 24.92 | 68.70B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.47 | 46.87B |
Related stock screener links
About RVPH
Company Profile
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 14 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Company Info
REVIVA PHARMACEUTICALS HOLDI
10080 N Wolfe Road, Suite Sw3-200
Cupertino CALIFORNIA 95014 US
CEO: Laxminarayan Bhat
Employees: 14
Phone: 14085018881
REVIVA PHARMACEUTICALS HOLDI / RVPH FAQ
What is the stock price of REVIVA PHARMACEUTICALS HOLDI today?
The current stock price of RVPH is 0.4916 USD. The price decreased by -3.61% in the last trading session.
What is the ticker symbol for REVIVA PHARMACEUTICALS HOLDI stock?
The exchange symbol of REVIVA PHARMACEUTICALS HOLDI is RVPH and it is listed on the Nasdaq exchange.
On which exchange is RVPH stock listed?
RVPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REVIVA PHARMACEUTICALS HOLDI stock?
12 analysts have analysed RVPH and the average price target is 8.6 USD. This implies a price increase of 1648.81% is expected in the next year compared to the current price of 0.4916. Check the REVIVA PHARMACEUTICALS HOLDI stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REVIVA PHARMACEUTICALS HOLDI worth?
REVIVA PHARMACEUTICALS HOLDI (RVPH) has a market capitalization of 33.43M USD. This makes RVPH a Nano Cap stock.
How many employees does REVIVA PHARMACEUTICALS HOLDI have?
REVIVA PHARMACEUTICALS HOLDI (RVPH) currently has 14 employees.
What are the support and resistance levels for REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?
REVIVA PHARMACEUTICALS HOLDI (RVPH) has a support level at 0.5 and a resistance level at 0.54. Check the full technical report for a detailed analysis of RVPH support and resistance levels.
Should I buy REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RVPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RVPH, evaluating the profitability, health, valuation and growth aspects
- REVIVA PHARMACEUTICALS HOLDI (RVPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REVIVA PHARMACEUTICALS HOLDI (RVPH) Sales and EPS estimates to see what analysts future expectations are.
- REVIVA PHARMACEUTICALS HOLDI (RVPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REVIVA PHARMACEUTICALS HOLDI (RVPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Chart to make your own analysis
- REVIVA PHARMACEUTICALS HOLDI (RVPH) Latest news and press-releases to stay up to date.
Does REVIVA PHARMACEUTICALS HOLDI (RVPH) stock pay dividends?
RVPH does not pay a dividend.
When does REVIVA PHARMACEUTICALS HOLDI (RVPH) report earnings?
REVIVA PHARMACEUTICALS HOLDI (RVPH) will report earnings on 2025-11-12.
What is the Price/Earnings (PE) ratio of REVIVA PHARMACEUTICALS HOLDI (RVPH)?
REVIVA PHARMACEUTICALS HOLDI (RVPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).
What is the Short Interest ratio of REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?
The outstanding short interest for REVIVA PHARMACEUTICALS HOLDI (RVPH) is 27.76% of its float. Check the ownership tab for more information on the RVPH short interest.
RVPH Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RVPH. When comparing the yearly performance of all stocks, RVPH is a bad performer in the overall market: 97.3% of all stocks are doing better.
RVPH Financial Highlights
Over the last trailing twelve months RVPH reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -233.02% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RVPH Forecast & Estimates
12 analysts have analysed RVPH and the average price target is 8.6 USD. This implies a price increase of 1648.81% is expected in the next year compared to the current price of 0.4916.